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Abstract
Background: Acute kidney injury (AKI) is one of the serious postoperative complications in patients 
undergoing heart valve surgery. The aim of the present study was to identify selected biomarkers to 
predict AKI requiring renal replacement.
Methods: A prospective study was conducted on a group of 751 patients undergoing heart valve sur-
gery. The data on risk factors, preoperative complete blood count, course of operations and postoperative 
period was assessed. The primary endpoint at the 30-day follow-up was postoperative AKI requiring 
renal replacement therapy. The secondary end-point was death from all causes in patients with postop-
erative AKI requiring renal replacement.
Results: The primary endpoint occurred in 46 patients. At multivariate analysis: age, red cell distri-
bution width (RDW) and C-reactive protein remained independent predictors of the primary endpoint. 
Hemoglobin and RDW were associated with an increased risk of death.
Conclusions: Elevated RDW is associated with a higher risk of postoperative AKI and death in pa-
tients with AKI. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
Acute kidney injury (AKI) in patients un-
dergoing heart valve surgery is one of the seri-
ous postoperative complications associated with 
prolonged hospitalization, increased mortality as 
well as the occurrence of chronic kidney disease 
[1–3]. The diagnosis of AKI is based on two func-
tional markers, an increase of serum creatinine 
and a reduction of urinary excretion. Predictors 
of perioperative AKI in patients undergoing heart 
surgery include preoperative creatinine level, end-
stage renal disease, 2-2 phenotype of haptoglobin, 
advanced age, diabetes mellitus, congestive heart 
failure, generalized atherosclerosis, cardiovascular 
collapse, nitric oxide, cyanotic heart disease, dura-
tion of surgery and elevated postoperative lactate 
level [4–9]. In patients with severe AKI, oliguria 
and fluid accumulation, renal replacement therapy 
is the basic method of treatment [10]. Hemodia-
filtration seems to represent the gold standard in 
the field of replacement of renal function in patients 
undergoing heart valve surgery [11–13]. 
Red cell distribution width (RDW) is a param-
eter that reflects the variability of the size of red 
blood cells (anisocytosis). Elevated RDW is a result 
of erythrocytes production dysfunction related to a 
deficiency of folic acid, iron, vitamin B12 or ongoing 
inflammation as well as increased destruction of 
erythrocytes e.g. in the course of hemolysis. Previ-
ous studies have indicated the predictive ability of 
RDW in various cardiovascular disorders [14–24]. 
Identifying risk factors for developing AKI and ag-
gressive early intervention is extremely important 
to optimize outcomes in patients with heart valve 
disease. Therefore, the aim of the present study 
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was to identify and evaluate selected biomarkers 
to predict AKI requiring renal replacement therapy 
in patients undergoing heart valve surgery.
Methods
A prospective study was conducted on a group 
of consecutive patients with hemodynamically 
significant valvular heart disease (aortic stenosis, 
aortic regurgitation, mitral stenosis and/or mitral 
regurgitation) that qualified for cardiac surgery 
and subsequently underwent elective replacement 
or repair of a valve/valves. The exclusion criteria 
were: patients under 18 years of age, a lack of 
consent to participate in the study, hemolytic 
disease, blood transfusion before surgery in the 
last 3 months, active neoplastic diseases, autoim-
mune diseases, chronic inflammatory bowel and 
active endocarditis. One day prior to surgery a 
blood sample for biomarkers was collected from 
each patient. Full blood counts were measured 
from K2EDTA samples using a Sysmex K-4500 
electronic counter. The glomerular filtration rate 
(GFR) was estimated based on a simplified MDRD 
pattern: GFR (mL/min/1.73 m2) = 186.3 × [cre-
atinine concentration (mg/dL)] – 1.154 × [age 
(years)] – 0.203 × C, where C stood: for men — 1, 
for women — 0.742. Chronic renal failure was de-
fined as chronic (lasting at least 3 months) impaired 
renal function, understood as a reduction in GFR 
< 60 mL/min/1.73 m2 and included the following 
stages of chronic kidney disease (CKD), stage 3 
CKD (GFR 45–59 mL/min/1.73 m2), stage 3b CKD 
(GFR 30–44 mL/min/1.73 m2), stage 4 CKD (GFR 
15–29 mL/min/1.73 m2) and stage 5 CKD (GFR 
< 15 mL/min/1.73 m2). AKI was diagnosed as an 
increase in serum creatinine (SCr) by at least 0.3 
mg/dL (26.5 μmol/L) within 48 h or a urine volume 
of less than 0.5 mL/kg/h for 6 h. The decision to 
start hemodiafiltration was made by the team of 
anesthesiologists responsible for the patient with 
the diagnosis of AKI and persisting high param-
eters of the kidneys (creatinine and/or urea) and 
anuria despite intensive conservative treatment. 
Continuous veno-venous hemodiafiltration was 
performed in all of the patients qualifying for renal 
replacement therapy. The primary end-point was 
perioperative AKI requiring renal replacement 
therapy. The secondary end-point was death from 
all causes in patients with perioperative renal 
replacement therapy. Patient follow-up was for 30 
days or until death. The follow-up of discharged 
patients was conducted through direct observation 
during hospitalization and clinic visits for 30 days 
subsequent to surgery. The study was conducted 
at the Institute of Cardiology, Warsaw, Poland 
between January 1 2014 and September 30 2018. 
The protocol was approved by The Institutional 
Ethics Committee.
Statistical analysis
Statistical analysis was performed using the 
SAS version 9.2. Data are presented as the mean 
± standard deviation and frequency (percentage). 
The Shapiro-Wilk test of normality was used to test 
sample distribution. Intergroup comparisons were 
made using the Mann–Whitney U test, the Pear-
son’s c2 test or Student t-test. Delta 1 RDW value 
(D1RDW) defined as RDW measured 48 h after sur-
gery minus preoperative RDW. Delta 2 RDW value 
(D2RDW) defined as RDW measured 94 h after sur-
gery minus preoperative RDW. Logistic regression 
was used to assess relationships between variables. 
The following covariates: age, aortic cross-clamp 
time, cardiopulmonary bypass time, preoperative 
atrial fibrillation, body mass index (BMI), GFR, 
chronic obstructive airways disease, coronary 
artery disease, current smoker, dyslipidemia, 
EuroSCORE II, hypertension, insulin dependent 
diabetes mellitus, left ventricular ejection frac-
tion, New York Heart Association (NYHA) classes, 
peripheral atherosclerosis, previous myocardial 
infarction, pulmonary blood pressure, stroke his-
tory, total cholesterol, creatinine, high sensitivity 
troponin T, C-reactive protein (CRP), hematocrit, 
hemoglobin, mean corpuscular hemoglobin, mean 
corpuscular volume, platelets, preoperative RDW, 
RDW measured 48 h after surgery (RDW1), RDW 
measured 96 h after surgery (RDW2), D1RDW, 
D2RDW and white blood cell count were investi-
gated for association with endpoints in univariate 
analysis. Significant determinants (p < 0.05) iden-
tified from univariate analysis were subsequently 
entered into multivariate models. Predictive value 
of RDW was assessed by a comparison of the areas 
under the receiver operator characteristics of the 
respective curve. On the basis of the Youden index, 
a cut-off point was determined that met with the 
criterion of maximum sensitivity and specificity for 
perioperative renal replacement therapy.
Results
The study group included 751 consecutive 
patients who underwent replacement or repair 
of a valve/valves. The mean age was 63.5 ± 13 
(Table 1). Two hundred twenty (29%) patients 
had preoperative chronic renal failure (stage 3a 
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Table 1. Baseline characteristics of the study population.
Characteristics of patients (n = 751) Values Values  
with RRT
Values  
without RRT
P
Age [years] 63.5 ± 13 69 ± 10 61 ± 13 0.002
Male: men 426 (57%) 22 (47%) 404 (57%) NS
Body mass index [kg/m2] 27 ± 9 26 ± 7 27 ± 10 NS
NYHA (classes) 2.6 ± 0.5 2.8 ± 0.8 2.4 ± 0.5 0.004
LV ejection fraction [%] 56 ± 12 54 ± 13 58 ± 10 NS
Pulmonary blood pressure [mmHg] 43 ± 17 55 ± 19 40 ± 9 0.005
EuroSCORE II [%] 3.55 ± 3.4 7 ± 5 3 ± 2 0.006
Atrial fibrillation 318 (42%) 33 (71%) 285 (40%) 0.004
Chronic renal failure (GFR < 60 mL/min/1.73 m2) 220 (29%) 25 (54%) 195 (27%) 0.03
Chronic obstructive airways disease 42 (6%) 4 (8%) 38 (5%) NS
Coronary artery disease 185 (24%) 9 (19%) 176 (25%) NS
Peripheral atherosclerosis 55 (7%) 5 (7%) 38 (6%) NS
Previous myocardial infarction 79 (10%) 6 (13%) 73 (10%) NS
Stroke history 50 (7%) 1 (2%) 49 (7%) NS
Hypertension 468 (62%) 26 (56%) 442 (62%) NS
Insulin dependent diabetes mellitus 26 (3%) 1 (2%) 25 (3%) NS
Current smoker 145 (19%) 8 (15%) 137 (29%) NS
Cholesterol (total) [mmol/L] 4.7 ± 0.9 4.4 ±  1.2 4.8 ± 0.9 0.03
Hematocrit [%] 46 ± 10 37 ± 13 47 ± 9 0.001
Hemoglobin [g/dL] 13.7 ± 1.5 12.2 ± 1.8 14 ± 1.4 0.003
RDW [%] 13.8 ± 1.1 15.5 ± 2 13.5 ± 1.0 < 0.001
RDW1 [%] 14.2 ± 1.3 15.8 ± 2.1 14 ± 1.4 0.01
RDW2 [%] 14.4 ± 1.4 15.9 ± 2.2 14.1 ± 1.3 0.04
D1RDW 0.4 ± 0.2 0.3 ± 0.1 0.5 ± 0.4 NS
D2RDW 0.6 ± 0.3 0.4 ± 0.2 0.6 ± 0.3 NS
C-reactive protein [mmol/L] 93 ± 32 136 ± 48 90 ± 28 0.002
CRP [mg/dL] 0.44 ± 0.35 0.89 ± 0.6 0.34 ± 0.3 0.002
Hs-TnT [ng/L] 36 ± 28 73 ± 52 22 ± 17 0.003
Platelets [1000/uL] 192 ± 60 188 ± 58 195 ± 62 NS
Aortic cross-clamp time [min] 91 ± 39 94 ± 41 89 ± 30 NS
Cardiopulmonary bypass time [min] 115 ± 45 121 ± 46 112 ± 42 0.04
Hemodiafiltration time [days] 3 ± 2
Main procedures
AVR 219 (29%) 15 (32%) 204 (28%) NS
AVR + supracoronary ascending aortic replacement 82 (11%) 3 (7%) 79 (11%) NS
AVP  4 (0.5%)
Bentall procedure 55 (7%)
David procedure 5 (0.6%)
AVR + MVR 68 (9%) 9 (19%) 79 (11%) 0.4
AVR + MVP 17 (2%)
AVP + MVP 7 (1%)
MVP 149 (20%) 9 (20%) 140 (19%) ns
MVR 145 (19%) 10 (21%) 135 (19%) ns
Concomitant procedures
Coronary artery bypass grafting 104 (14%) 14 (30%) 90 (12%) 0.4
The values are represented by the mean and a measure of the variation of the internal standard deviation. AVR — aortic valve replacement; 
AVP — aortic valve plasty; GFR — glomerular filtration rate; Hs-TnT — high sensitivity troponin T; LV — left ventricle; MVR — mitral valve re-
placement; MVP — mitral valve plasty; NYHA — New York Heart Association; RDW — red cell distribution width (preoperative); RDW1 — red 
cell distribution width measured 48 hours after surgery; RDW2 — red cell distribution width measured 96 h after surgery; D1RDW — defined 
as RDW measured 48 h after surgery — preoperative RDW; D2RDW — defined as RDW measured 96 h after surgery — preoperative RDW; 
RRT — renal replacement therapy
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Figure 1. Area under receiver operating characteris-
tic curve of red cell distribution width for a renal re-
placement therapy following valve replacement/repair 
surgery.
Table 2. Analysis of predictive factors for the occurrence of postoperative renal replacement therapy.
Variable Univariate analysis Multivariate analysis
Odds ratio 95% Cl P Odds ratio 95% Cl P
Age [years] 1.066 1.031–1.103 0.002 1.082 1.019–1.162 0.02
CBT [min] 1.202 1.101–1.303 0.04
CRP [mg/dL] 2.442 1.546–3.556 0.002 2.386 1.416–3.268 0.04
Creatinine [mmol/L] 1.160 1.094–1.242 0.001
GFR [mL/min/1.73 m2] 0.944 0.927–0.962 0.004
Hemoglobin [g/dL] 0.595 0.491–0.721 0.001
LVEF [%] 0.966 0.944–0.988 0.003
RDW [%] 1.697 1.290–2.233 0.0002 1.578 1.208–2.544 0.003
RDW1 [%] 1.798 1.135–2.448 0.009
CBT — cardiopulmonary bypass time; CRP — C-reactive protein; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; 
RDW — red cell distribution width (preoperative); RDW1 — red cell distribution width measured 48 h after surgery
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CKD — 151 patients, stage 3b CKD — 52 patients, 
stage 4 CKD — 17 patients and stage 5 CKD — 0 
patients). All procedures were performed through 
a midline sternotomy incision under general anes-
thesia in normothermia. The mean preoperative 
RDW level was 13.8% ± 1.1. Table 1 shows char-
acteristics of patients studied. Forty-six patients 
required renal replacement therapy (25 patients 
with preoperative chronic renal failure). The 
statistically significant predictors of postopera-
tive renal replacement therapy at univariate and 
multivariate analysis are presented in Table 2. 
At multivariate analysis: age (odds ratio [OR] 1.082; 
95% confidence interval [CI] 1.019–1.162; p = 
0.02), RDW (OR 1.578; 95% CI 1.208–2.544; p = 
0.003) and CRP (OR 2.386; 95% CI 1.416–3.268; 
p = 0.04) remained independent predictors of the 
primary endpoint. The optimal cut-off point for 
postoperative renal replacement therapy was calcu-
lated at > 14.3% RDW (sensitivity 80%, specificity 
76%). The area under receiver operator character-
istic curve for postoperative AKI requiring renal 
replacement therapy for RDW is 0.804 (95% CI 
0.772–0.832) (Fig. 1). Twenty-eight patients with 
AKI requiring renal replacement therapy died in 
30-day follow-up (15 patients with preoperative 
chronic renal failure). Cause of death in all patients 
was the increasing multi-organ failure. Statistically 
significant predictors of death from all causes in 
patients with postoperative renal replacement 
therapy at univariate and multivariate analysis 
are presented in Table 3. At multivariate analy-
sis, hemoglobin (OR 1.015; 95% CI 1.004–1.026; 
p = 0.01) and RDW (OR 1.288; 95% CI 1.152–1.422; 
p = 0.04) remained predictors of mortality.
Discussion
Acute kidney injury requiring renal replace-
ment therapy is a common and significant complica-
tion after heart valve surgery. The present study 
revealed that this complication was seen in 6% of 
patients following heart valve surgery. The aim 
of this study was the evaluation and identification 
of predictors perioperative AKI requiring renal 
replacement therapy in the early postoperative 
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ability of cells to defend against the strong stress 
of hypoxia [30]. The reserve is very important in 
such stressful situations such as heart valve sur-
gery. Elevated RDW, meant to reflect a reduced 
physiological reserve, may explain the fact of 
a higher incidence of serious complications in the 
postoperative period, such as postoperative AKI. 
Conclusions
Red cell distribution width is a parameter 
that reflects the variability of the size of red blood 
cells (anisocytosis). Elevated RDW is a result of 
erythrocytes production dysfunction related to 
a deficiency of folic acid, iron, vitamin B12 or ongo-
ing inflammation as well as increased destruction 
of erythrocytes e.g. in the course of hemolysis. 
The results of this study indicate that the RDW 
is a useful parameter for estimating the risk of 
postoperative renal replacement therapy and renal 
replacement therapy-related mortality in patients 
undergoing heart valve surgery. This was a single-
center study that included a limited number of 
participating patients. In future studies, enlarging 
the group may allow confirmation of the results 
obtained. Further studies are needed to clarify 
the pathomechanisms linking an increased risk of 
perioperative renal replacement therapy in patients 
with a higher RDW. 
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